Mylan Insists Complex Generics Strategy Is Poised To Deliver

With one high-profile approval in its pocket – a version of Teva's blockbuster Copaxone – Mylan's management believes its strategy of investing in complex generics and biosimilars will help the company navigate challenges in the US generic market.

Business Balance - A businessman carrying paperwork walking over a tight rope.

Mylan NV's plan to invest in complex generics and biosimilars is about to begin paying dividends, helping ease the company through the challenging US commercial market for small molecule generic drugs, at least that was the message management, including CEO Heather Bresch and President Rajiv Malik, tried to deliver to investors during the company's third quarter earnings call Nov. 6.

The company is hoping to ride the positive momentum coming off the FDA approval of a generic version of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

Stock Watch: Vaccine Skepticism Confounds Commercial Prospects For Shingrix And Gardasil

 
• By 

The US political environment and vaccine hesitancy by the general population have affected the sale of safe vaccines with clinical utility and no competition. The confusion and contradictions in the recent ACIP meeting are likely to stoke these pressures further.

Top 10 Drugs Q2 2025: Mounjaro Overtakes Ozempic

 

Eli Lilly’s Mounjaro overtook rival GLP-1 agonist Ozempic from Novo Nordisk to become the second-highest selling drug globally in the second quarter of 2025, while overall GLP-1 drug sales continued to swell.

Stock Watch: Is First To Market Always Best?

 
• By 

The first approved anti-PD-1 antibody to market eased ahead of later entrants by sales. But efficacy, tolerability and ease of administration are factors that count beyond first-mover advantage.

Norway’s Nykode Upbeat About Cancer Vaccines After Tough Year

 
• By 

The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.

More from Business

Ribomic Positions Itself As Latest Potential Achondroplasia Competitor

 

The company announced positive Phase II data for umedaptanib pegol and plans to move it into Phase III development in fiscal year 2026.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By 

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.

Stock Watch: Baby Steps In Most Favored Nation Drug Pricing

 
• By 

Raising UK drug prices and offering lower list prices only to those US patients who are under- or uninsured were the industry’s initially cosmetic answers to the administration’s most favored nation drug pricing challenge. Then Pfizer stepped in.